Seizure News and Research

Latest Seizure News and Research

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

GSK, Valeant receive European CHMP positive opinion for Trobalt

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™ (retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

21 Jan 2011

Australians urged to vaccinate babies and care givers against whooping cough

The number of cases of the deadly whooping cough in the Hume region in Victoria, including Wodonga, last year increased fivefold from those diagnosed in 2008. A total 67 cases were reported in Albury last year but across the Greater Southern region there were more than 1,000 cases. The outbreak reached its peak in September. In the last three years 1,416 West Australians contracted the disease, three of whom died.

18 Jan 2011

ETP introduces online epilepsy diary management tool to advance patient care

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy and seizures and the parent organization of epilepsy.com, today announced that it has expanded the use of its online epilepsy diary management tool with the launch of a new app developed to run on the Android mobile operating system.

18 Jan 2011

U.S. Marshals seize Rite-Dent's dental devices

U.S. Marshals, acting under a court order sought by the U.S. Food and Drug Administration, on Jan. 5 and 6, seized all dental devices from Rite-Dent Manufacturing Corporation, located in Hialeah, Fla.

14 Jan 2011

FDA approves Cumberland's Acetadote Injection

Cumberland Pharmaceuticals today announced that it has received approval from the U.S. Food and Drug Administration for a new formulation of Acetadote Injection, the Company's product used to treat acetaminophen poisoning.

13 Jan 2011

Adjunctive lacosamide reduces seizures and improves responder rates

Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs.

13 Jan 2011

Aβ, tau and Fyn protein interactions may lead to brain dysfunction and AD

Though the cause of Alzheimer's disease still is unknown, recent studies have implicated three proteins strongly in its onset. New research from the University of Alabama at Birmingham, the Gladstone Institutes and the Baylor College of Medicine indicates that interactions between those three proteins might lead to brain dysfunction and AD in a mouse model of the disease.

13 Jan 2011

Maternal depression adversely affects quality of life in children with epilepsy

A study by Canadian researchers examined the prevalence of maternal depression and its impact on children newly diagnosed with epilepsy. Prevalence of depression in mothers ranged from 30%-38% within the first 24 months following a child’s epilepsy diagnosis. The mother’s depressive symptoms negatively impacted the child’s health-related quality of life, but the effects were moderated by the amount of family resources and mediated by how well the family functions and the extent of family demands. Details of this novel study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

5 Jan 2011

Child's epilepsy diagnosis impacts mother's mental health and family environment

5 Jan 2011

Removal of ZIP proteins from hippocampus cell protects them from injury

Researchers in the Blue Bird Circle Developmental Neurogenetics Laboratory in the department of neurology at Baylor College of Medicine have discovered that zinc enters cells through specialized protein gates known as ZIP transporters, and removing these ZIP proteins from cells in the hippocampus significantly protects them from injury.

5 Jan 2011

General anesthesia's similarities with and differences from sleep and coma

The use of general anesthesia is a routine part of surgical operations at hospitals and medical facilities around the world, but the precise biological mechanisms that underlie anesthetic drugs' effects on the brain and the body are only beginning to be understood. A review article in the December 30 New England Journal of Medicine brings together for the first time information from a range of disciplines, including neuroscience and sleep medicine, to lay the groundwork for more comprehensive investigations of processes underlying general anesthesia.

30 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

The test strips being recalled may give falsely low blood glucose results. False results may lead patients to try to raise their blood glucose unnecessarily, or they may fail to treat elevated blood glucose because of a false, low reading. Both scenarios pose risks to a patient's health.

22 Dec 2010

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (acetylcysteine) Injection to treat patients with non-acetaminophen induced acute liver failure.

22 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

Food stored at rodent-infested warehouse seized by U.S. Marshals

U.S. Marshals, acting under a court order sought by the U.S. Food and Drug Administration, today seized chili pods, ground chili, crushed chili, and other chili products located in the rodent-infested food warehouse owned by Duran and Sons LLC in Derry, New Mexico. The New Mexico Environment Department had previously placed an embargo on all products in the company's food warehouse on Nov. 17, 2010.

14 Dec 2010

Appeals Court upholds preliminary injunction against FDA to stop seizure of electronic cigarettes

In a straightforward decision, a Federal Appeals Court has upheld a preliminary injunction against the FDA to stop the seizure of the electronic cigarette as it enters the country to suppliers that retail them to the smoking public.

9 Dec 2010

New finding could help identify individuals with abnormal brain function

Mayo Clinic researchers found that the part of the brain generating seizures in individuals with epilepsy is functionally isolated from surrounding brain regions. The researchers hope this finding could be a clinical biomarker to help identify individuals with abnormal brain function.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010